Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Phase 1

Completed

Conditions: Lymphoblastic Leukemia, Acute, Childhood
Peripheral T-cell Lymphoma
Lymphoblastic Lymphoma

Interventions: Drug: Temsirolimus
Drug: Etoposide
Drug: Cyclophosphamide
Drug: Methotrexate
Drug: Hydrocortisone
Drug: Cytarabine

First Posted Date: 2012-06-07

Last Posted Date: 2023-07-27

Lead Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Target Recruit Count: 16

Registration Number: NCT01614197

Locations: 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, United States
🇺🇸
Lurie Children's Hospital, Chicago, Illinois, United States

and more 29 locations

Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

Phase 2

Completed

Conditions: Central Nervous System Nongerminomatous Germ Cell Tumor
Childhood Central Nervous System Germinoma

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Carboplatin
Drug: Etoposide
Drug: Ifosfamide
Radiation: Intensity-Modulated Radiation Therapy

First Posted Date: 2012-05-21

Last Posted Date: 2024-11-19

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 262

Registration Number: NCT01602666

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

and more 164 locations

Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma

Phase 1

Completed

Conditions: Recurrent Hepatosplenic T-Cell Lymphoma
Mycosis Fungoides
Recurrent Anaplastic Large Cell Lymphoma
Refractory Angioimmunoblastic T-Cell Lymphoma
Refractory Hepatosplenic T-Cell Lymphoma
Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
Refractory Anaplastic Large Cell Lymphoma
Refractory Enteropathy-Associated T-Cell Lymphoma
Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Recurrent Enteropathy-Associated T-Cell Lymphoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Drug: Ifosfamide
Drug: Romidepsin

First Posted Date: 2012-05-03

Last Posted Date: 2018-09-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT01590732

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Capecitabine
Drug: Etoposide

First Posted Date: 2012-05-01

Last Posted Date: 2017-02-27

Lead Sponsor: Tao OUYANG

Target Recruit Count: 54

Registration Number: NCT01589159

Locations: 🇨🇳
Peking University Cancer Hospital & Institute, Beijing, Beijing, China

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)

Phase 1

Terminated

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: Roniciclib (BAY1000394)
Drug: Etoposide
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2012-04-09

Last Posted Date: 2021-04-08

Lead Sponsor: Bayer

Target Recruit Count: 43

Registration Number: NCT01573338

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

Phase 2

Completed

Conditions: Hodgkin Lymphoma

Interventions: Drug: Etoposide
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone
Drug: Dexamethasone
Drug: Dacarbazine
Drug: Procarbazine
Drug: Brentuximab Vedotin

First Posted Date: 2012-04-03

Last Posted Date: 2018-10-29

Lead Sponsor: University of Cologne

Target Recruit Count: 100

Registration Number: NCT01569204

Locations: 🇩🇪
1st Dept. of Medicine, Cologne University Hospital, Cologne, Germany

Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Radiation: Proton Beam Radiation
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2012-03-29

Last Posted Date: 2016-02-17

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 4

Registration Number: NCT01565772

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)

Phase 3

Conditions: Extensive-Stage Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Palifosfamide-tris
Drug: Etoposide

First Posted Date: 2012-03-15

Last Posted Date: 2013-05-21

Lead Sponsor: Alaunos Therapeutics

Target Recruit Count: 548

Registration Number: NCT01555710

Locations: 🇺🇸
Medical Oncology Associates Of Wyoming Valley, PC, Kingston, Pennsylvania, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Swedish Medical Center, Seattle, Washington, United States

and more 76 locations